JP2011500550A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500550A5
JP2011500550A5 JP2010528515A JP2010528515A JP2011500550A5 JP 2011500550 A5 JP2011500550 A5 JP 2011500550A5 JP 2010528515 A JP2010528515 A JP 2010528515A JP 2010528515 A JP2010528515 A JP 2010528515A JP 2011500550 A5 JP2011500550 A5 JP 2011500550A5
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutically acceptable
use according
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010528515A
Other languages
English (en)
Japanese (ja)
Other versions
JP5883222B2 (ja
JP2011500550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2008/054138 external-priority patent/WO2009047723A2/en
Publication of JP2011500550A publication Critical patent/JP2011500550A/ja
Publication of JP2011500550A5 publication Critical patent/JP2011500550A5/ja
Application granted granted Critical
Publication of JP5883222B2 publication Critical patent/JP5883222B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010528515A 2007-10-10 2008-10-09 心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体 Expired - Fee Related JP5883222B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007054130 2007-10-10
IBPCT/IB2007/054130 2007-10-10
PCT/IB2008/054138 WO2009047723A2 (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Publications (3)

Publication Number Publication Date
JP2011500550A JP2011500550A (ja) 2011-01-06
JP2011500550A5 true JP2011500550A5 (enExample) 2011-10-20
JP5883222B2 JP5883222B2 (ja) 2016-03-09

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528515A Expired - Fee Related JP5883222B2 (ja) 2007-10-10 2008-10-09 心的外傷後ストレス障害の治療のためのテトラヒドロキノリン誘導体

Country Status (27)

Country Link
US (1) US9532985B2 (enExample)
EP (1) EP2207550B1 (enExample)
JP (1) JP5883222B2 (enExample)
KR (1) KR101733247B1 (enExample)
CN (1) CN101820878B (enExample)
AR (1) AR068768A1 (enExample)
AU (1) AU2008309194B2 (enExample)
BR (1) BRPI0818617A2 (enExample)
CA (1) CA2699504C (enExample)
CY (1) CY1114799T1 (enExample)
DK (1) DK2207550T3 (enExample)
EA (1) EA017443B1 (enExample)
ES (1) ES2444418T3 (enExample)
HR (1) HRP20140214T1 (enExample)
IL (1) IL204838A (enExample)
MA (1) MA31800B1 (enExample)
MX (1) MX2010003711A (enExample)
MY (1) MY153044A (enExample)
NZ (1) NZ585086A (enExample)
PE (1) PE20091010A1 (enExample)
PL (1) PL2207550T3 (enExample)
PT (1) PT2207550E (enExample)
SI (1) SI2207550T1 (enExample)
TW (1) TWI428129B (enExample)
UA (1) UA99150C2 (enExample)
WO (1) WO2009047723A2 (enExample)
ZA (1) ZA201003251B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380391T3 (es) 2006-12-22 2012-05-11 Actelion Pharmaceuticals Ltd. Derivados de 5,6,7,8-tetrahidro-imidazo[1,5-a]pirazina
US20110105514A1 (en) 2008-06-25 2011-05-05 Hamed Aissaoui 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
TW201209037A (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
SI2626350T1 (sl) 2010-09-22 2015-09-30 Eisai R&D Management Co., Ltd. Spojina ciklopropana
WO2012063207A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012085852A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
DK2776430T3 (en) 2011-11-08 2016-05-09 Actelion Pharmaceuticals Ltd 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists
TWI570120B (zh) 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
JP6496733B2 (ja) 2013-12-03 2019-04-03 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd (s)−(2−(6−クロロ−7−メチル−1h−ベンゾ[d]イミダゾール−2−イル)−2−メチルピロリジン−1−イル)(5−メトキシ−2−(2h−1,2,3−トリアゾール−2−イル)フェニル)メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
KR102330133B1 (ko) 2013-12-04 2021-11-23 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체의 용도
SG10202007759RA (en) 2014-10-23 2020-09-29 Eisai R&D Man Co Ltd Compositions and methods for treating insomnia
CN115710250A (zh) * 2017-08-01 2023-02-24 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6011301A (en) * 2000-03-14 2001-09-24 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinoline derivatives
AU2004224156B2 (en) * 2003-03-26 2010-08-12 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
JP4094050B2 (ja) * 2004-03-01 2008-06-04 アクテリオン ファーマシューティカルズ リミテッド 置換1,2,3,4−テトラヒドロイソキノリン誘導体
US7501395B2 (en) * 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
EP1998774A1 (en) 2006-03-15 2008-12-10 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinoline derivatives to enhance memory function
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist

Similar Documents

Publication Publication Date Title
JP2011513410A5 (enExample)
HRP20140214T1 (hr) Derivati tetrahidrokinolina za lijeäśenje posttraumatskog stresnog poremeä†aja
JP2016505614A5 (enExample)
JP2010529147A5 (enExample)
JP2016006118A5 (enExample)
JP2008501000A5 (enExample)
JP2014521744A5 (enExample)
JP2012507535A5 (enExample)
JP2013523733A5 (enExample)
JP2012041349A5 (enExample)
JP2012530705A5 (enExample)
JP2018135343A5 (enExample)
JP2015531774A5 (enExample)
JP2013502441A5 (enExample)
JP2012530758A5 (enExample)
JP2017517538A5 (enExample)
JP2012512863A5 (enExample)
JP2010521516A5 (enExample)
JP2014510055A5 (enExample)
JP2013544854A5 (enExample)
JP2016503403A5 (enExample)
JP2012509265A5 (enExample)
JP2016537338A5 (enExample)
JP2008536833A5 (enExample)
JP2016535040A5 (enExample)